Am J Psychiatry 160:290-296, February 2003
© 2003 American Psychiatric Association
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Jean-Pierre Lindenmayer, M.D.,
Pal Czobor, Ph.D.,
Jan Volavka, M.D., Ph.D.,
Leslie Citrome, M.D., M.P.H.,
Brian Sheitman, M.D.,
Joseph P. McEvoy, M.D.,
Thomas B. Cooper, M.A.,
Miranda Chakos, M.D., and
Jeffrey A. Lieberman, M.D.
OBJECTIVE: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors’ goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. METHOD: One hundred fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hospitals were originally included in the study. The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period. Planned assessments included fasting glucose and cholesterol, which were collected at baseline and at the end of the 8-week period and the following 6-week period. RESULTS: One hundred eight of the 157 patients provided blood samples at baseline and at least at one point after random assignment to clozapine, olanzapine, risperidone, or haloperidol during the treatment trial. Seven of these patients had diabetes; their glucose levels were >125 mg/dl at baseline. Data from 101 patients were used for statistical analyses. During the initial 8-week period there was an overall significant increase in mean glucose levels. There were significant increases in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) and those given haloperidol (N=25). The olanzapine group showed a significant increase of glucose levels at the end of the 6-week variable-dose period (N=22). Fourteen of the 101 patients developed abnormal glucose levels (>125 mg/dl) during the trial (six with clozapine, four with olanzapine, three with risperidone, and one with haloperidol). Cholesterol levels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27) and those given olanzapine (N=26); cholesterol levels were also increased at the end of the 6-week variable-dose period for patients given olanzapine (N=22). CONCLUSIONS: In this prospective randomized trial, clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels. The mean changes in glucose and cholesterol levels remained within clinically normal ranges, but approximately 14% of the patients developed abnormally high glucose levels during the course of their participation in the study.
This article has been cited by other articles:
|
|
|
|
 
R. Rohrbaugh, D. G. Federman, L. Borysiuk, and M. Sernyak
Utilizing VA Information Technology to Develop Psychiatric Resident Prescription Profiles
Acad Psychiatry,
January 1, 2009;
33(1):
27 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yang, J. C Barner, K. A Lawson, K. L Rascati, J. P Wilson, M L. Crismon, J. Worchel, and C. A Mascarenas
Antipsychotic Medication Utilization Trends Among Texas Veterans: 1997-2002
Ann. Pharmacother.,
September 1, 2008;
42(9):
1229 - 1238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Mackin, D. Bishop, H. Watkinson, and I. Ferrier
A prospective study of glycaemic status in anti-psychotic-treated patients
J Psychopharmacol,
July 1, 2008;
22(5):
563 - 566.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Smith, D. Hopkins, R. C. Peveler, R. I. G. Holt, M. Woodward, and K. Ismail
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis
The British Journal of Psychiatry,
June 1, 2008;
192(6):
406 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weber, M. Colon, and M. Nelson
Pilot Study of a Cognitive Behavioral Group Intervention to Prevent Further Weight Gain in Hispanic Individuals With Schizophrenia
Journal of the American Psychiatric Nurses Association,
January 1, 2008;
13(6):
353 - 359.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Ojala, E. Repo-Tiihonen, J. Tiihonen, and L. Niskanen
Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents
J Psychopharmacol,
January 1, 2008;
22(1):
33 - 38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. L Citrome, R. I. Holt, W. M Zachry, J. D Clewell, P. A Orth, J. L Karagianis, and V. P. Hoffmann
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Ann. Pharmacother.,
October 1, 2007;
41(10):
1593 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. OLFSON, S. C. MARCUS, P. COREY-LISLE, A.S. TUOMARI, P. HINES, and G. J. L'ITALIEN
Dr. Olfson and Colleagues Reply
Am J Psychiatry,
March 1, 2007;
164(3):
526 - 526.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. RICO-VILLADEMOROS and E. P. CALANDRE
Confounding by Indication and the Risk of Hyperlipidemia in Observational Studies of Antipsychotics
Am J Psychiatry,
March 1, 2007;
164(3):
525 - 526.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Kim, A. S. Huang, A. M. Snowman, C. Teuscher, and S. H. Snyder
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
PNAS,
February 27, 2007;
104(9):
3456 - 3459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Olfson, S. C. Marcus, P. Corey-Lisle, A.V. Tuomari, P. Hines, and G. J. L'Italien
Hyperlipidemia Following Treatment With Antipsychotic Medications
Am J Psychiatry,
October 1, 2006;
163(10):
1821 - 1825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Holt
Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome
The British Journal of Diabetes & Vascular Disease,
September 1, 2006;
6(5):
199 - 204.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. L. Olson, T. Delate, and D. J. Duagn
Monitoring of Patients Given Second-Generation Antipsychotic Agents
Psychiatr Serv,
July 1, 2006;
57(7):
1045 - 1046.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Weissman, D. M. Moot, and S. M. Essock
What Do People With Schizophrenia Think About Weight Management?
Psychiatr Serv,
May 1, 2006;
57(5):
724 - 725.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Cohen, R. P. Stolk, D. E. Grobbee, and C. C. Gispen-de Wied
Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Diabetes Care,
April 1, 2006;
29(4):
786 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Gianfrancesco, J. Pesa, R.-H. Wang, and H. Nasrallah
Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design
Am. J. Health Syst. Pharm.,
March 1, 2006;
63(5):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A Marken and R. W Pies
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Ann. Pharmacother.,
February 1, 2006;
40(2):
276 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Llorente and V. Urrutia
Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications
Clin. Diabetes,
January 1, 2006;
24(1):
18 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Zipursky, H. Gu, A. I. Green, D. O. Perkins, M. F. Tohen, J. P. McEvoy, S. M. Strakowski, T. Sharma, R. S. Kahn, R. E. Gur, et al.
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
The British Journal of Psychiatry,
December 1, 2005;
187(6):
537 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe and C. Paton
The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
76 - 83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Citrome
Metabolic Syndrome and Cardiovascular Disease
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
84 - 93.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Freedman
The Choice of Antipsychotic Drugs for Schizophrenia
N. Engl. J. Med.,
September 22, 2005;
353(12):
1286 - 1288.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. REMINGTON
Rational pharmacotherapy in early psychosis
The British Journal of Psychiatry,
August 1, 2005;
187(48):
s77 - s84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Rugino and Y. M. Janvier
Aripiprazole in Children and Adolescents: Clinical Experience
J Child Neurol,
July 1, 2005;
20(7):
603 - 610.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Akhtar, C. Kelly, A. Gallagher, and J. R Petrie
Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk
The British Journal of Diabetes & Vascular Disease,
September 1, 2004;
4(5):
303 - 309.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Smith and T. White
Low glycaemic index diet in patients prescribed clozapine: pilot study
Psychiatr. Bull.,
August 1, 2004;
28(8):
292 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.H. Belmaker
Bipolar Disorder
N. Engl. J. Med.,
July 29, 2004;
351(5):
476 - 486.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E Lee, S. S Gill, M. Freedman, S. E Bronskill, M. P Hillmer, and P. A Rochon
Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review
BMJ,
July 10, 2004;
329(7457):
75.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe and R. Holt
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s67 - s71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe and B. Leonard
Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s87 - s93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gough and R. Peveler
Diabetes and its prevention: pragmatic solutions for people with schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s106 - s111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Diabetes Care,
February 1, 2004;
27(2):
596 - 601.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L Citrome and A. B Jaffe
Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus
Ann. Pharmacother.,
December 1, 2003;
37(12):
1849 - 1857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Freedman
Schizophrenia
N. Engl. J. Med.,
October 30, 2003;
349(18):
1738 - 1749.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. VOLAVKA, P. CZOBOR, J.-P. LINDENMAYER, L. CITROME, J. P. McEVOY, T. B. COOPER, and J. A. LIEBERMAN
Dr. Volavka and Colleagues Reply
Am J Psychiatry,
March 1, 2003;
160(3):
592 - 593.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
